Acquisition by Adams Helen C of 20000 shares of Immix Biopharma subject to Rule 16b-3
| IMMX Stock | USD 2.25 0.03 1.32% |
Slightly above 63% of Immix Biopharma's investor base is looking to short. The analysis of the overall investor sentiment regarding Immix Biopharma suggests that many traders are alarmed. Immix Biopharma's investing sentiment can be driven by a variety of factors including economic data, Immix Biopharma's earnings reports, geopolitical events, and overall market trends.
Immix |
Filed transaction by Immix Biopharma Inc director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Immix Biopharma Fundamental Analysis
We analyze Immix Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immix Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immix Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
Immix Biopharma is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Immix Biopharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Immix Biopharma stock to make a market-neutral strategy. Peer analysis of Immix Biopharma could also be used in its relative valuation, which is a method of valuing Immix Biopharma by comparing valuation metrics with similar companies.
Peers
Immix Biopharma Related Equities
| CNSP | Cns Pharmaceuticals | 9.09 | ||||
| ZVSA | ZyVersa Therapeutics | 4.07 | ||||
| HEPA | Hepion Pharmaceuticals | 8.20 | ||||
| OCEA | Ocean Biomedical | 9.46 | ||||
| ELEV | Elevation Oncology | 9.64 | ||||
| SONN | Sonnet Biotherapeutics | 12.92 | ||||
| ENVB | Enveric Biosciences | 16.00 |
Additional Tools for Immix Stock Analysis
When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.